Form 4: Oramed Pharmaceuticals Chief Scientific Officer Receives 30,000 Restricted Stock Units
SEC Form 4 Filing
Miriam Kidron, Chief Scientific Officer of Oramed Pharmaceuticals, reports the acquisition of 30,000 Restricted Stock Units (RSUs) that vest on November 7, 2024.
Summary
- Miriam Kidron, the Chief Scientific Officer of Oramed Pharmaceuticals, filed a Form 4 on November 8, 2024.
- The report details a transaction on November 7, 2024, where she acquired 30,000 Restricted Stock Units (RSUs).
- These RSUs will vest on November 7, 2024, and convert into common stock on a one-for-one basis.
- Following this transaction, Kidron beneficially owns 793,666 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock options, indicating a neutral sentiment.
Industry Context
This is a standard disclosure related to executive compensation and equity ownership, common in the pharmaceutical industry.
Key Dates
| Date | Description |
|---|---|
| 11/07/2024 | Date of transaction: Miriam Kidron acquired 30,000 Restricted Stock Units (RSUs) and the vesting date of the RSUs. |
| 11/08/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.